<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317276</url>
  </required_header>
  <id_info>
    <org_study_id>GNE AD 431</org_study_id>
    <nct_id>NCT02317276</nct_id>
  </id_info>
  <brief_title>A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal</brief_title>
  <acronym>GNE-AD</acronym>
  <official_title>A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the differential expression of AD biomarkers in serum,
      plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD
      patients in the presence of TCS and after withdrawal from TCS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory study consists of four visits to the investigator site post screening: at
      Weeks 0 (baseline), 2, 6 and 8 (Figure 1). At the first visit (baseline), patients who have
      met the screening eligibility criteria will be started on a stable TCS regimen for a total of
      two weeks. At the second visit (Week 2) following two weeks of therapy on stable TCS,
      patients will stop TCS and blood, serum, plasma and two 6mm punch biopsies (one lesional (L)
      and one non-lesional (NL) skin) will be obtained. At the third visit (Week 6), after four
      weeks receiving no TCS, the same sample collections will be repeated and the patients will
      then enter a two week safety follow up. At the end of the safety follow up (last visit, Week
      8) and after obtaining written informed consent by the patient, blood, serum and plasma
      samples mav be collected.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to meet the study's recruitment goals
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 6, 2017</completion_date>
  <primary_completion_date type="Actual">April 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With Topical Corticosteroids.</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immunoglobulin E (IgE), Interleukin 13 (IL-13), Chemokine ligand 13 (CCL-13), and Chemokine ligand 17 (CCL-17). These biomarkers will be evaluated for differential gene expression and protein levels in samples obtained from atopic dermatitis patients on and off topical corticosteroid treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone 0.1%</intervention_name>
    <description>Topical ointment</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Triamcinolone 0.1% ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 18-75 years of age

          2. AD diagnosed by the Rajka/Hanifin criteria at the time of screening and that has been
             present for at least 1 year

          3. History of inadequate response to a stable regimen of TCS for 1 month (in the 3 months
             immediately preceding the screening visit) as treatment for their AD

          4. Eczema Area and Severity Index (EASI) score ≥ 14 at the screening and baseline visits

          5. Investigator's Global Assessment (IGA; 5-point) score ≥ 3 at the screening and
             baseline visits

          6. ≥10% body surface area involvement by AD

          7. A washout period prior to screening for those patients who have previously received
             the following medications:

               -  Cyclosporine/Oral Steroids/Imuran/Mycophenolate Mofetil/Other systemic
                  immunosuppressants: 4 weeks

               -  Phototherapy: 4 weeks

               -  Biologics: 5 half lives of the drug

        Exclusion Criteria:

          1. Evidence of other concomitant skin conditions (e.g., psoriasis or contact dermatitis)

          2. Use of topical calcineurin inhibitors within 4 weeks of screening

          3. Hypersensitivity to TCS or to any other ingredients contained by the emollient or TCS
             product used during the study

          4. Evidence of active skin infection at screening or baseline visit

          5. Evidence or history of active or latent infections such as tuberculosis or hepatitis C

          6. Patient clinical condition is not appropriate for treatment with protocol prescribed
             TCS

          7. Use of an investigational agent within 4 weeks prior to screening or within 5
             half-lives of the investigational agent, whichever is longer

          8. Use of a tanning booth/parlor within 4 weeks before the baseline visit

          9. Use of any anti-histamine medication within 4 weeks before the baseline visit.

         10. History of any condition (e.g. bleeding diathesis) that may predispose the patient to
             complications associated with the planned skin biopsy procedures

         11. Known current malignancy or current evaluation for a potential malignancy, including
             basal or squamous cell carcinoma of the skin or carcinoma in situ

         12. Other clinically significant medical disease that is uncontrolled despite treatment
             that is likely, in the opinion of the investigator, to impact the patient's ability to
             participate in the study or to impact the study pharmacodynamic (PD), or safety
             assessments

         13. Unwillingness or inability to comply with the study protocol for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Arron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Dermatology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081.</citation>
    <PMID>18385500</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams DL, Ozment-Skelton T, Li C. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock. 2006 May;25(5):432-9. Review.</citation>
    <PMID>16680006</PMID>
  </results_reference>
  <results_reference>
    <citation>Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010 Mar;26(3):633-40. doi: 10.1185/03007990903512156. Review.</citation>
    <PMID>20070141</PMID>
  </results_reference>
  <results_reference>
    <citation>Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum (EDF); European Academy of Dermatology and Venereology (EADV); European Federation of Allergy (EFA); European Task Force on Atopic Dermatitis (ETFAD); European Society of Pediatric Dermatology (ESPD); Global Allergy and Asthma European Network (GA2LEN). Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60. doi: 10.1111/j.1468-3083.2012.04635.x.</citation>
    <PMID>22805051</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, Novak N, Bernstein D, Blessing-Moore J, Khan D, Lang D, Nicklas R, Oppenheimer J, Portnoy J, Randolph C, Schuller D, Spector S, Tilles S, Wallace D. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013 Feb;131(2):295-9.e1-27. doi: 10.1016/j.jaci.2012.12.672. Review.</citation>
    <PMID>23374261</PMID>
  </results_reference>
  <results_reference>
    <citation>Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, Mitsui H, Cardinale I, de Guzman Strong C, Krueger JG, Guttman-Yassky E. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012 Dec;130(6):1344-54. doi: 10.1016/j.jaci.2012.07.012. Epub 2012 Aug 27.</citation>
    <PMID>22951056</PMID>
  </results_reference>
  <results_reference>
    <citation>Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, Liu FT, Arron JR. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol. 2012 Dec;130(6):1335-43.e5. doi: 10.1016/j.jaci.2012.06.044. Epub 2012 Aug 22.</citation>
    <PMID>22920495</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <results_first_submitted>November 26, 2018</results_first_submitted>
  <results_first_submitted_qc>January 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2019</results_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02317276/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>For this study we recruited participants from UCSF Dermatology Clinic, and by posting advertisements online</recruitment_details>
      <pre_assignment_details>There was a washout period prior to screening for those patients who have previously received the following medications:
Cyclosporine/Oral Steroids/Imuran/Mycophenolate Mofetil/Other systemic immunosuppressants: 4 weeks
Phototherapy: 4 weeks
Biologics: 5 half lives of the drug</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
Triamcinolone 0.1%: Topical ointment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
Triamcinolone 0.1%: Topical ointment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eczema Area and Severity Index (EASI)</title>
          <description>The EASI score measures extent of eczema involvement and severity of eczema signs, per body region. The body regions are head/neck, trunk, upper extremities, and lower extremities. Area of eczema involvement is scored as a % where 1= 1-9% involvement, 2= 10-29%, 3= 30-49%, 4= 50-69%, 5= 70-89%, 6= 90-100%. Severity of eczema signs is scored as number 0-3 where 0=none, 1=mild, 2=moderate, 3=severe. The % and severity are then added and multiplied with a multiplier for a total score. The total score ranges from 0-72. A higher score indicates more involved and more severe eczema, a worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment (IGA)</title>
          <description>The Investigator's Global Assessment (IGA) is a 5-point scale measuring disease severity (in this case, eczema severity). A score of 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. The number given is the score (not added or multiplied, and half points/scores cannot be used). A higher score indicates more severe eczema and a worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With Topical Corticosteroids.</title>
        <description>The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immunoglobulin E (IgE), Interleukin 13 (IL-13), Chemokine ligand 13 (CCL-13), and Chemokine ligand 17 (CCL-17). These biomarkers will be evaluated for differential gene expression and protein levels in samples obtained from atopic dermatitis patients on and off topical corticosteroid treatment.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>No samples were analyzed for the primary outcome measure of change in blood and tissue levels. Since the study was terminated, the blood and tissue samples were not analyzed as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
Triamcinolone 0.1%: Topical ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With Topical Corticosteroids.</title>
          <description>The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immunoglobulin E (IgE), Interleukin 13 (IL-13), Chemokine ligand 13 (CCL-13), and Chemokine ligand 17 (CCL-17). These biomarkers will be evaluated for differential gene expression and protein levels in samples obtained from atopic dermatitis patients on and off topical corticosteroid treatment.</description>
          <population>No samples were analyzed for the primary outcome measure of change in blood and tissue levels. Since the study was terminated, the blood and tissue samples were not analyzed as planned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 1 year, during the duration of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
Triamcinolone 0.1%: Topical ointment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to our inability to meet the sponsor's recruitment goals, the study was terminated and no data was analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarah Arron, MD, PhD</name_or_title>
      <organization>UCSF Dermatology</organization>
      <phone>415-353-9684</phone>
      <email>Sarah.Arron@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

